根据公开信息，此前复星国际于2月27日斥资4823.54万港元回购1302.7万股。公告显示，自2022年1月1 日起至本次公告，复星国际已累计回购2.58859亿股，约占已发行股份总数的3.17%，总金额约11.9亿港 元。 本次公告同时强调，"在现行估值水准下实施回购符合本公司及股东整体利益。" 在创新药赛道，研发突破与全球市场拓展齐头并进。例如，旗下生物创新药平台复宏汉霖与卫材株式会 社就H药汉斯状达成协议，布局日本这一全球第四大医药市场，潜在总金额超3亿美元。而在2025年， 复星的创新药商业化更是打开了巨大的全球市场空间，与辉瑞签订的全球独家许可协议潜在总金额超20 亿美元，与生物技术公司Clavis Bio达成的战略合作，可获得至多72.5亿美元付款。 在文旅消费赛道，复星多个产品线取得新年开门红，有望拉动今年板块业绩的增长。其中，上海豫园商 城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假村春 节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增长 20%，创下历史最佳表现。 此外，在保险赛道，复星国内 ...

行 业 及 产 业 海外消费服务 行 业 研 究 / 行 业 点 相关研究 证 券 研 究 报 告 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 周文远 A0230518110003 zhouwy@swsresearch.com 贾梦迪 A0230520010002 jiamd@swsresearch.com 研究支持 胡梦婷 A0230524060004 humt@swsresearch.com 联系人 胡梦婷 A0230524060004 humt@swsresearch.com 2026 年 03 月 01 日 海外社服：澳门春节假期的总访客量和日均访客量创 历史新高 看好 ——海外消费周报（20260220-20260226） 本期投资提示： ⚫ 海外社服：澳门春节假期的总访客量和日均访客量创历史新高 澳门春节期间的总入境旅客量和日均旅客量都创下了有史以来的新高。总入境旅客量 155.4 万人 次，日均旅客量 17.3 万人次，可比口径同比增长 5.5%。入境旅客中，内地旅客日均 13.4 万人 次，同比增长 7%；国际旅客日均接近 7,900 人次 ...

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising nearly 2% and achieving a trading volume exceeding 750 million yuan, indicating renewed investor interest [1][3]. Group 1: Company Developments - Innovent Biologics announced a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [3]. - The stock performance of key companies within the ETF is positive, with Innovent Biologics up over 4%, BeiGene and China National Pharmaceutical Group up over 3%, and CSPC Pharmaceutical Group and Hansoh Pharmaceutical up over 1% [3][4]. Group 2: Industry Trends - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," with a projected increase in License-out transactions from $2.562 billion in 2017 to $140.274 billion by 2025, indicating a significant leap in global recognition [5]. - By 2025, over 70% of companies in the innovative drug sector are expected to achieve revenue growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, showcasing strong commercialization capabilities [6]. - The innovative drug sector is entering a phase of profitability, with companies like Innovent Biologics and Rongchang Biologics achieving breakeven, while others like Elysium and Rongchang Biologics maintain robust growth [9][11]. Group 3: Investment Opportunities - The innovative drug sector is expected to see a surge in clinical data releases in 2026, with major academic conferences likely to provide further validation for domestic innovative drugs [8]. - Investment strategies should focus on core areas such as small nucleic acids, bispecific antibodies, and ADCs, while also capitalizing on performance forecast windows to identify high-potential stocks [8][12].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant increases in License-out transaction values from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in the first week of February 2026, with a 0.14% increase, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In 2026, the upfront payment for License-out transactions has already exceeded 39% of the total for 2025, indicating improved quality and competitiveness of Chinese innovative drug pipelines [5][15][16] Section 2: Performance of the Pharmaceutical Sector - The innovative drug sector is experiencing rapid revenue growth, with companies like BeiGene achieving over 36 billion yuan in revenue, showcasing strong commercialization capabilities [6][23] - Major companies such as Innovent Biologics and Rongchang Biopharma have maintained robust growth due to their core products, with some companies achieving profitability for the first time [6][23][24] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the traditional Chinese medicine sector saw the highest increase at 2.56%, while other biopharmaceutical sectors experienced declines [7][31] - The medical research outsourcing sector also performed well, with a 1.99% increase, indicating a positive trend in the pharmaceutical industry overall [7][31][35]

Core Insights - Hubei Jichuan Pharmaceutical Co., Ltd. has secured exclusive commercialization rights for two innovative drugs, Inusimab injection and Pumexitin (PG-011) nasal spray, enhancing its product portfolio [1][2][3] Group 1: Commercialization Agreements - Jichuan Pharmaceutical signed an exclusive commercialization agreement for Inusimab injection, a PCSK9 monoclonal antibody for treating primary hypercholesterolemia and mixed dyslipidemia, with a payment of 80 million yuan (including tax) and potential milestone payments of up to 10 million yuan [2] - The Inusimab injection is expected to be approved for market launch in September 2024 and included in the National Medical Insurance Drug List in 2025 [2] - Jichuan Pharmaceutical also signed an exclusive commercialization agreement for Pumexitin nasal spray, a JAK1/2 inhibitor for allergic rhinitis, with a payment of up to 100 million yuan (including tax) [3] Group 2: Financial Performance and Challenges - Jichuan Pharmaceutical's core products have faced declining sales, leading to a decrease in revenue and net profit. In 2024, the company reported an operating revenue of 8.017 billion yuan, down 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [8] - The sales of key products, including Pudilan anti-inflammatory oral liquid and pediatric Qiqiao Qingre granules, have been negatively impacted by market demand changes and pricing policies, resulting in significant revenue declines [8][9] - In the first three quarters of 2025, the company continued to experience a downward trend, with operating revenue of 3.932 billion yuan, down 32.27%, and a net profit of 1.022 billion yuan, down 46.27% [9]

Core Insights - Haichuang Pharmaceutical's innovative drug, Deutetrabenazine (brand name: Hainan'an®), has successfully passed GMP compliance inspection, enabling large-scale commercial production [1] - The drug has been included in the 2025 National Medical Insurance Directory, providing a solid payment foundation for market expansion [1] - The combination of GMP certification and insurance inclusion creates a synergistic effect, completing the company's full industry chain from R&D to production and sales [1] Group 1: Product and Market Potential - Deutetrabenazine is the first domestic AR inhibitor approved for metastatic castration-resistant prostate cancer (mCRPC), filling a clinical gap in this area [2] - The domestic AR inhibitor market is rapidly growing, expected to reach 23.9 billion yuan by 2030, with the overall prostate cancer market exceeding 50 billion yuan [2] - The current market is dominated by foreign products, which hold 75% of the market share, indicating significant potential for domestic alternatives [2] Group 2: Pipeline Development - The activation of commercial production capacity will support not only the core product but also the pipeline reserves, ensuring scalable implementation [3] - The oral ARPROTAC drug HP518 is in clinical trials, showing potential for synergy with Deutetrabenazine in treating resistant prostate cancer [3] Group 3: Metabolic Disease Research - The drug HP515 for treating MASH has completed Phase I clinical trials, with Phase II trials ongoing, showcasing promising preclinical data in combination with GLP-1 drugs [4] - The combination therapy addresses the core issue of muscle loss associated with traditional weight loss drugs, catering to the needs of over 400 million overweight/obese individuals in China [5] - The global weight loss market is projected to reach $554.9 billion by 2030, indicating substantial growth potential in this sector [5] Group 4: Strategic Positioning - The dual breakthroughs of GMP certification and core product insurance inclusion signify the company's comprehensive capabilities in innovative R&D, large-scale production, and market promotion [5] - The company aims to leverage its mature production management system and full industry chain layout to enhance market penetration of core products and clinical transformation of pipeline products [5]

摘要 康哲药业 2025 年实现正增长，毛利率和净利润改善，预计全年收入和 利润增长趋势明显。创新药商业化和国际化是未来主要增长驱动力，已 有五款创新药商业化，六款产品处于 NDA 阶段，数十项产品在临床阶段。 公司预计 2025-2027 年归母净利润分别为 16.5 亿元、19.6 亿元和 22.7 亿元，实现稳健增长。公司早期为 CSO 平台，后转型关注产品创 新、国际化及商业革新，2024 年进入创新产品商业化元年。 公司产品线包括存量国产品、独家或品牌产品及创新药。五款创新药自 2023 年陆续上市，预计 2025 年合计收入翻倍。研发管线丰富，包括 NDA 阶段及临床三期阶段的多项重磅新品。 心脑血管领域核心产品包括波依定、达力新、新活素等，总销售收入约 30 多亿元。维福瑞和维妥可表现突出，实现快速增长。德西杜斯塔片及 治疗 AD 等相关疾病的新疗法将丰富治疗方案。 创新药维福瑞用于透析后高磷血症，患者接受度高，副作用少，峰值销 售额有望超 20 亿元。注射用 Y3 治疗缺血性脑卒中，预防卒中后抑郁和 焦虑，预计峰值销售额可达 20-30 亿元。 Q&A 康哲药业在 2025 年上半年的业绩表现 ...

核心产品国内商业化合作落地，看好未来 销售潜力 众生药业点评报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 张澄(分析师) | 010-58067988 | zhangcheng5@gtht.com | S0880525040130 | | 彭娉(分析师) | 021-23185619 | pengping@gtht.com | S0880525040080 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | 本报告导读： 公司核心减重创新药产品 RAY1225 国内商业化权益授予齐鲁制药，合作总包金额 达 10 亿元，再度验证产品临床价值与未来商业化潜力。 投资要点： [Table_Market] 交易数据 | 52 周内股价区间(元) | 10.45-26.61 | | --- | --- | | 总市值(百 ...